Clinical trial
Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With…
NCT02075255 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT02075255 |
|---|---|
| Title | Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy |
| Official title | A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Biological |
| Interventions | Benralizumab, Placebo |
| Enrollment | 220 |
| Start date | Apr 28, 2014 |
| Primary completion | Aug 8, 2016 |
| Completion | Aug 8, 2016 |
| First posted | Mar 3, 2014 |
| Last update posted | Jun 8, 2018 |
| Countries | Argentina, Bulgaria, Canada, Chile, France, Germany, Poland, South Korea, Spain, Turkey (Türkiye), Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: